Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar;57(6):733-734.
doi: 10.1111/apt.17351.

Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure?

Kenneth Ernest-Suarez  1 , Cathy Lu  1
Affiliations
Editorial

Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure?

Kenneth Ernest-Suarez et al. Aliment Pharmacol Ther. 2023 Mar.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Juillerat P, Grueber MM, Ruetsch R, Santi G, Vuillèmoz M, Michetti P. Positioning biologics in the treatment of IBD: a practical guide-which mechanism of action for whom? Curr Res Pharmacol Drug Discovery. 2022;3:100104.
    1. Buisson A, Nachury M, Guilmoteau T, Altwegg R, Treton X, Fumery M, et al. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent. Aliment Pharmacol Ther. 2023;57(6):676-88.
    1. Straatmijer T, Biemans VBC, Visschedijk M, Hoentjen F, de Vries A, van Bodegraven A, et al. Initiative on Crohn and colitis superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF-experienced ulcerative colitis patients: a Nationwide Dutch registry study. Clin Gastroenterol Hepatol. 2022. May 26;S1542-3565(22)00510-9. https://doi.org/10.1016/j.cgh.2022.04.038
    1. Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;18:2179-2191.e6.
    1. Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2022; 71:1976-1987.

LinkOut - more resources